Little Green Pharma Ltd

LGP.ASX

Health Care

Cultivation and production of medicinal cannabis products

Market Data

Price

$0.076

-0.0%
Market Cap

$64.3M

P/E Ratio

-100000.0x

EPS

$-0.005

Div. Yield

0.00%

52-Week Change

-0.3%

Latest Earnings

Appendix 4E and 2026 Annual Report

21 May 2026

Revenue
$42,491
+15.3% YoY
NPAT
-$1,408
-142.4% YoY

Little Green Pharma delivered strong FY2026 results with record revenue of $42.5M (+15.3% YoY) and Adjusted EBITDA of $6.5M (up 124% from $2.9M), though net profit swung to a loss of $1.4M from prior year profit of $3.3M due to inventory write-downs and share-based payments. Europe emerged as the primary growth driver, with German and UK markets performing strongly, while the company maintains a solid balance sheet with net tangible assets of 23.29 cents per share. Key points: Record revenue of $42.5M, up 15.3% YoY driven by strong international market growth; Adjusted EBITDA increased significantly to $6.5M from $2.9M (124% growth), demonstrating operational leverage; Europe emerged as primary growth driver, with European revenue exceeding Australian revenue in Q4; Germany and UK showing strong demand

Recent Announcements

16 Jun 2026 Sph Neutral

Notice of ceasing to be a substantial holder

Ms Fleta Jennfifer Solomon ceased to be a substantial holder.

21 May 2026 Actual Results Positive

Appendix 4E and 2026 Annual Report

Little Green Pharma delivered strong FY2026 results with record revenue of $42.5M (+15.3% YoY) and Adjusted EBITDA of $6.5M (up 124% from $2.9M), though net profit swung to a loss of $1.4M from prior year profit of $3.3M due to inventory write-downs and share-based payments. Europe emerged as the primary growth driver, with German and UK markets performing strongly, while the company maintains a solid balance sheet with net tangible assets of 23.29 cents per share. Key points: Record revenue of $42.5M, up 15.3% YoY driven by strong international market growth; Adjusted EBITDA increased significantly to $6.5M from $2.9M (124% growth), demonstrating operational leverage; Europe emerged as primary growth driver, with European revenue exceeding Australian revenue in Q4; Germany and UK showing strong demand

Get real-time alerts for LGP

Receive AI-powered earnings summaries and instant notifications when Little Green Pharma Ltd releases results.

Register Free